Trevor Hoey | If the Australian market gets the staggers, expect sharp share price declines from these stocks.

Trevor Hoey | Share price impact of move, flagged as far back as February, expected to be nominal.

Christina Zhou | Record mark follows a solid March quarter and despite signs of a slowing market.

Rebecca Thistleton | There’s no magic formula to investing in the right places, but there are trends.

Jonathan Shapiro | Global debt investors pile into sub-prime Australian mortgages in search of higher returns.

Jonathan Shapiro | The winners in global bonds over 12 months have been the losers in the past four.

Bianca Hartge-Hazelman | Consolidation in local mining is creating a serious shortage of investment opportunities.

Jared Lynch | Gold stocks are up and about in 2014, but there are doubts over how far the rally has to go.

Trevor Hoey | There have been signs in the past few weeks that the childcare landscape may have changed.

Jeremy Chunn | ETF investors who attempt to change their strategy may only be fooling themselves.

Phil Coorey | May budget will increase means testing, introduce co-payments for benefits and slash spending.

Sally Patten | Good chance funds will deliver fifth consecutive positive return with just one quarter remaining.

| Jaws dropped at AMP HQ late last week on news of Queensland adviser Rhys Wood’s submission to the Financial System Inquiry. Wood, who is the director of a financial planning company licensed by AMP, accused groups of directing advisers to use in-house products. But it must have been a misunderstanding, or a reference to some other institution, because we’ve heard Wood say in the past that he “doesn’t feel any pressure to sell AMP products”. In fact, it turns out he joined AMP early last year because of its focus on “acting in the best interests of clients”. Looking at closely at AMP’s approved products list, which includes more than 550 investment options, only 192 or a little more than one-third are AMP branded. Who says there’s a problem?

| The savage sell down of biotech stock QRxPharma has many investors talking about the quality of the sector’s analysts, with one in particular coming under particular scrutiny. The analyst has been talking up a handful of prospects recently, including QRxPharma, which fell 80 per cent after US authorities knocked back its product MOXDUO, a combination of potent painkillers morphine and oxycodone. The analyst hadn’t considered that possibility (despite two pervious knock backs) and earlier this month told clients that the FDA’s upcoming meeting would simply “discuss and recommend MOXDUO”. Smart Investor spoke to a fund manager who recently sold his entire biotech holdings, citing this particular analyst as a reason for losing faith in the sector. A little too close to the company, perhaps?